Life Technologies' Ion Proton™ to Power Stratified Medicine Scotland Innovation Centre

Life Technologies' Ion Proton™ to Power Stratified Medicine Scotland 
Innovation Centre 
Innovation Centre's ambitious approach to treatment of disease to dramatically 
improve patient outcomes whilst reducing overall healthcare costs. 
GLASGOW, Scotland, April 23, 2013 /CNW/ - Life Technologies Corporation 
(NASDAQ: LIFE) today announces that it is a lead commercial partner along with 
Aridhia, a bio-medical informatics company, in the Stratified Medicine 
Scotland Innovation Centre (SMS-IC). The Ion Proton™ sequencing platform 
will be the primary tool to drive discovery and genetic analysis as SMS-IC 
aspires to be a world-class centre of research, innovation and 
commercialisation in stratified medicine.  The SMC-IC is a unique 
collaboration bringing together excellence in the academic, industrial and NHS 
communities to create an infrastructure that will act as a springboard to 
allow Scotland to be at the forefront of the field. 
The First Minister of Scotland, Alex Salmond said: "Scotland has always been a 
world leader in innovation and this new funding for the Stratified Medicine 
Scotland Innovation Centre reinforces the Scottish Government's commitment to 
the Life Sciences securing Scotland's place as a world leader in innovative 
health technology. The pioneering research carried out by the innovation 
centres will not only improve the healthcare of patients but also, by way of 
the unique advanced process of diagnosis, could potentially save lives." 
"The Stratified Medicine Scotland Innovation Centre is a ground breaking 
project that represents a real opportunity to change the way healthcare will 
be practiced," said Peter Silvester, President Europe, Middle East & Africa of 
Life Technologies. "Life Technologies will provide facilities and the genetic 
analysis platform with its semiconductor based, Ion Proton™ DNA sequencing 
technology, at a speed, accuracy and cost that would have been impossible just 
a few months ago.  The vision for this project is to combine an individual's 
detailed genomic data with more traditional patient information to enable 
faster, more accurate and effective clinical decisions.  This is an inflection 
point in the history of medical research, and there is much more to come." 
Stratified medicine is recognised as a key strategic approach to the future 
diagnosis and treatment of disease and depends critically upon information; 
the integration of existing data sets to form a comprehensive 'personal' 
healthcare record and the generation of new data describing patient 
characteristics - genotype and phenotype - to permit 'stratification.' 
Scotland's past investment in electronic health records (EHRs) and 
translational medicine research, coupled with a vibrant healthcare technology 
industry, positions Scotland as the location to drive forward the stratified 
medicine agenda globally. The aim of SMS-IC is to prove the principle of 
stratified clinical trials and in 2013 it will begin a series of exemplar 
projects which link patient phenotype, genotypic and other data types enabling 
precision targeting of populations for clinical trials.  Although the Ion 
Proton™(  )platform is currently for Research Use Only, the ultimate aim is 
to take stratified clinical trial models from concept to clinical practice.  
SMS-IC will run a competition to identify suitable projects and applications 
are invited from interested parties. 
A semiconductor chip is at the heart of the Ion Proton's technology. Instead 
of relying on light-based technology and cameras to capture images of DNA 
sequences, the Ion Proton™ System translates chemical information into 
digital data. The chip enables sequencing to be performed on a massively 
parallel format, drastically accelerating the sequencing process. 
The Ion Proton™(  )is For Research Use Only, not intended for diagnostic 
purposes. 
About Life Technologies  Life Technologies Corporation (NASDAQ: LIFE) is a 
global biotechnology company that is committed to providing the most 
innovative products and services to leading customers in the fields of 
scientific research, genetic analysis and applied sciences. With a presence in 
more than 180 countries, the company's portfolio of 50,000 end-to-end 
solutions are secured by more than 5,000 patents and licenses that span the 
entire biological spectrum -- scientific exploration, molecular diagnostics, 
21(st )century forensics, regenerative medicine and agricultural research. 
Life Technologies has approximately 10,000 employees and had sales of $3.8 
billion in 2012. 
Life Technologies' Safe Harbor Statement  This press release includes 
forward-looking statements about our anticipated results that involve risks 
and uncertainties. Some of the information contained in this press release, 
including, but not limited to, statements as to industry trends and Life 
Technologies' plans, objectives, expectations and strategy for its business, 
contains forward-looking statements that are subject to risks and 
uncertainties that could cause actual results or events to differ materially 
from those expressed or implied by such forward-looking statements. Any 
statements that are not statements of historical fact are forward-looking 
statements. When used, the words "believe," "plan," "intend," "anticipate," 
"target," "estimate," "expect" and the like, and/or future tense or 
conditional constructions ("will," "may," "could," "should," etc.), or similar 
expressions, identify certain of these forward-looking statements. Important 
factors which could cause actual results to differ materially from those in 
the forward-looking statements are detailed in filings made by Life 
Technologies with the Securities and Exchange Commission. Life Technologies 
undertakes no obligation to update or revise any such forward-looking 
statements to reflect subsequent events or circumstances. 
(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO) 
Media Contacts: David Robertson Corporate Communications Europe, Middle East & 
Africa Life Technologies  Email: david.robertson@lifetech.com Tel: +44 141 814 
5889 
http://www.lifetechnologies.com 
http://photos.prnewswire.com/prnh/20110216/MM49339LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Life Technologies Corporation 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/April2013/23/c7792.html 
CO: Life Technologies Corporation
NI: HEA MTC BTC NP VNT  
-0- Apr/23/2013 08:16 GMT